Phenotypic Analysis of Circulating Myeloid Derived Suppressor Cells and Their Subpopulations in Egyptian Females with Breast Cancer: A Single-Centre Case-Control Study

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2024 Jan 29

PMID 38285792

Authors

Salma M Saed

Shimaa Abbas

Mervat S El Ansary

Walaa Abdelfattah

Karim K Maurice

Mohamed Emam Mohamed

Dina M Tawfik Koptan

Affiliations

Soon will be listed here.

Abstract

Background: Myeloid-derived suppressor cells (MDSC) are immature myeloid cells with suppressive function that has been thoroughly documented in the setting of cancer. Our purpose was to evaluate levels of MDSC and their subsets in a cohort of Egyptian patients with breast cancer.

Methods: Evaluation of peripheral blood total MDSC and its subset was done using multicolor flowcytometry in 30 malignant, 10 benign breast tumor patients and 10 healthy control females.

Results: BC patients had higher total MDSC levels compared to controls (p= 0.01) particularly the Monocytic MDSC (M-MDSC) and abnormal MDSC subsets (p = 0.001 and p <0.001, respectively). A tumor size > 2 cm exhibited significantly higher granulocytic MDSCs (G-MDSCs) compared to tumor size < 2 cm (p= 0.02) whereas abnormal MDSCs were significantly higher in patients with a tumor size < 2 cm (p = 0.037).

Conclusion: MDSC and its subsets can be used as a prognostic marker of tumor size as well as a potential targets for treatment in breast cancer patients.

References

Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L . The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Front Oncol. 2021; 11:610303. PMC: 7991834. DOI: 10.3389/fonc.2021.610303. View

Andersen M . Comment on "Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer". J Immunol. 2013; 190(11):5341. DOI: 10.4049/jimmunol.1390023. View

De Cicco P, Ercolano G, Ianaro A . The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. Front Immunol. 2020; 11:1680. PMC: 7406792. DOI: 10.3389/fimmu.2020.01680. View

Ostrand-Rosenberg S, Fenselau C . Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment. J Immunol. 2018; 200(2):422-431. PMC: 5765878. DOI: 10.4049/jimmunol.1701019. View

Hu M, Yao J, Cai L, Bachman K, van den Brule F, Velculescu V . Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet. 2005; 37(8):899-905. DOI: 10.1038/ng1596. View

Gatti-Mays M, Balko J, Gameiro S, Bear H, Prabhakaran S, Fukui J . If we build it they will come: targeting the immune response to breast cancer. NPJ Breast Cancer. 2019; 5:37. PMC: 6820540. DOI: 10.1038/s41523-019-0133-7. View

Miglietta F, Bottosso M, Griguolo G, Dieci M, Guarneri V . Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open. 2022; 7(2):100409. PMC: 8886005. DOI: 10.1016/j.esmoop.2022.100409. View

Sanchez-Leon M, Jimenez-Cortegana C, Silva Romeiro S, Garnacho C, de la Cruz-Merino L, Garcia-Dominguez D . Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells. Int J Mol Sci. 2023; 24(6). PMC: 10048951. DOI: 10.3390/ijms24065208. View

Susilowati S, Istiadi H, Suhartono S, Prajoko Y, Riwanto I, Susilaningsih N . The Role of Beetroot Extract in Overcoming Chemoresistance of Neoadjuvant Adriamycin Cyclophosphamide Regimen by Targeting Immune Response in Tumor Microenvironment: A Preclinical Study in Mammary Adenocarcinoma Rats. Asian Pac J Cancer Prev. 2022; 23(3):1061-1068. PMC: 9360944. DOI: 10.31557/APJCP.2022.23.3.1061. View

10.

Bevers T, Anderson B, Bonaccio E, Buys S, Buys S, Daly M . NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2009; 7(10):1060-96. DOI: 10.6004/jnccn.2009.0070. View

11.

Jin G, Zhang Y, Chang X, Zhang Y, Xu J, Wei M . Increased Percentage of mo-MDSCs in Human Peripheral Blood May Be a Potential Indicator in the Diagnosis of Breast Cancer. Oncol Res Treat. 2017; 40(10):603-608. DOI: 10.1159/000478933. View

12.

Mehmeti-Ajradini M, Bergenfelz C, Larsson A, Carlsson R, Riesbeck K, Ahl J . Human G-MDSCs are neutrophils at distinct maturation stages promoting tumor growth in breast cancer. Life Sci Alliance. 2020; 3(11). PMC: 7536824. DOI: 10.26508/lsa.202000893. View

13.

Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J . Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2018; 120(1):16-25. PMC: 6325125. DOI: 10.1038/s41416-018-0333-1. View

14.

Ballbach M, Dannert A, Singh A, Siegmund D, Handgretinger R, Piali L . Expression of checkpoint molecules on myeloid-derived suppressor cells. Immunol Lett. 2017; 192:1-6. DOI: 10.1016/j.imlet.2017.10.001. View

15.

Lorenzo-Sanz L, Munoz P . Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response. Cancer Microenviron. 2019; 12(2-3):119-132. PMC: 6937363. DOI: 10.1007/s12307-019-00232-2. View

16.

Elbasateeny S, Yassin M, Mokhtar M, Ismail A, Ebian H, Hussein S . Prognostic Implications of MALAT1 and BACH1 Expression and Their Correlation with CTCs and Mo-MDSCs in Triple Negative Breast Cancer and Surgical Management Options. Int J Breast Cancer. 2022; 2022:8096764. PMC: 8791720. DOI: 10.1155/2022/8096764. View

17.

Azim H, Elghazawy H, Ghazy R, Abdelaziz A, Abdelsalam M, Elzorkany A . Clinicopathologic Features of Breast Cancer in Egypt-Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis. JCO Glob Oncol. 2023; 9:e2200387. PMC: 10497263. DOI: 10.1200/GO.22.00387. View

18.

Jiang M, Zhang W, Zhang R, Liu P, Ye Y, Yu W . Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer. Oncogene. 2020; 39(24):4681-4694. DOI: 10.1038/s41388-020-1322-4. View

19.

Visvader J . Cells of origin in cancer. Nature. 2011; 469(7330):314-22. DOI: 10.1038/nature09781. View

20.

Bergenfelz C, Larsson A, von Stedingk K, Gruvberger-Saal S, Aaltonen K, Jansson S . Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients. PLoS One. 2015; 10(5):e0127028. PMC: 4439153. DOI: 10.1371/journal.pone.0127028. View